Cytori -Cell Therapy Technology
Cytori is developing cell therapies that harness the unique attributes of living cells that are present in an adult human patient’s own adipose (fat) tissue, also known as Adipose-Derived Regenerative Cells (ADRCs).
Cytori Cell Therapy is the collective name given to the fresh, heterogeneous population of ADRCs prepared with the proprietary Celution® System platform technology and administered to a patient for a specific disease or medical condition, all within a single day:
Cytori Cell Therapy is designed to repair injured tissue, preserve function, improve quality of life, and modify disease progression.
Physicians and scientists have demonstrated the frequency of stem cells in adipose (fat) tissue to be 2,500 times greater than the frequency of similar cells in bone marrow.1,2,3 Further, adipose (fat) tissue can be more easily collected than bone marrow via a small volume liposuction procedure.
Since Cytori technology prepares ADRCs exclusively from an adult human patient’s own adipose (fat) tissue, treatment with these cells avoids common transplantation issues, such as cell rejection or disease transmission, and does not require anti-rejection or immunosuppressant drugs.
While the exact mechanism of action is unknown, pre-clinical publications suggest the use of ADRCs has been associated with improvements in angiogenesis, inflammation, and fibrosis.
Cytori Cell Therapy is comprised of an autologous, heterogeneous, readily accessible cell population that is the result of more than a decade of rigorous research and development.
Advanced Technology, Convenient For the Patient
Cytori Cell Therapy is being developed to be delivered in a single treatment, designed to avoid the need for frequent re-treatment.
Cytori Cell Therapy eliminates the requirement for cells to be shipped to off-site facilities. Cells can be harvested in the hospital and processed on-site for faster care.
Safety Profile
The use of ADRCs in pre-clinical and clinical studies has been shown to be well-tolerated. Hundreds of patients have been treated with ADRCs in multiple clinical trials across the world. Cytori’s approach to cell therapy avoids the risk of rejection.